Financial Projections - The company expects 2025 annual revenue to be between 400 million and 420 million yuan, representing a year-on-year decrease of 17.79% to 21.71% compared to 2024[3]. - The projected net loss attributable to the parent company for 2025 is between 210 million and 230 million yuan, an increase in loss of 9.94% to 20.42% compared to the previous year[3]. - The expected net loss attributable to the parent company after deducting non-recurring gains and losses is between 250 million and 270 million yuan[3]. - In 2024, the company reported annual revenue of 510.9 million yuan and a net loss of 191 million yuan[4]. - The performance forecast is based on preliminary calculations by the finance department and has not been audited by an accounting firm[7]. - Investors are advised that the forecast data is preliminary and the final audited financial data will be disclosed in the 2025 annual report[8]. Performance Decline Factors - The decline in performance is primarily due to industry policy impacts, including price reductions and decreased demand in the in vitro diagnostic sector, as well as adjustments in tax policies affecting gross margins[6]. R&D Investments - The company increased its investment in the joint venture ShunJing Pharmaceutical, which has become a subsidiary, leading to significant R&D expense increases[6]. - The company’s joint ventures, including YaoJing Gene and ZhiYuan Bio, have intensified R&D investments in innovative drugs, contributing to increased investment losses[6].

Core Viewpoint - The company, Recbio, anticipates a significant decline in revenue and an increase in net losses for the year 2025, primarily due to industry policy changes and increased R&D investments [1] Financial Performance - Expected revenue for 2025 is projected to be between 400 million to 420 million yuan, representing a year-on-year decrease of 17.79% to 21.71% [1] - The net profit attributable to the parent company is forecasted to be between -210 million to -230 million yuan, indicating an increase in losses by 9.94% to 20.42% [1] - The non-recurring net profit is expected to range from -250 million to -270 million yuan [1] Factors Influencing Performance - The performance changes are mainly attributed to industry policies such as centralized procurement and tax policy adjustments, as well as impairment losses on operating assets [1] - Increased R&D investments following the capital increase in Shunjing Pharmaceutical and the consolidation of financial statements are also contributing factors [1] - The company has seen expanded investment losses due to increased R&D expenditures in joint ventures [1]

Core Viewpoint - The company, 热景生物 (Hotgen Biotech), is expected to experience a significant decline in revenue and an increase in net losses for the fiscal year 2025 compared to the previous year [1] Financial Performance - The projected revenue for 2025 is estimated to be between 400 million yuan and 420 million yuan, representing a year-on-year decrease of 17.79% to 21.71% [1] - The expected net profit attributable to the parent company for 2025 is forecasted to be between -210 million yuan and -230 million yuan, indicating an increase in losses of 9.94% to 20.42% compared to the previous year [1] - The net profit attributable to the parent company, after deducting non-recurring gains and losses, is anticipated to be between -250 million yuan and -270 million yuan for 2025 [1]

Group 1 - The core point of the news is that Beijing Hotgen Biotech Co., Ltd. experienced a stock decline of 5.12%, with a current share price of 179.31 yuan and a total market capitalization of 16.623 billion yuan [1] - The company specializes in the research, development, production, and sales of in vitro diagnostic reagents and instruments, with its main revenue sources being testing reagents (70.87%), testing instruments (19.79%), other (8.17%), and biological raw materials (1.17%) [1] Group 2 - According to data, Huaxia Fund has a significant holding in Hotgen Biotech, with the Huaxia SSE STAR 200 ETF (588820) increasing its stake by 28,000 shares in the third quarter, bringing the total to 29,600 shares, which represents 1.06% of the fund's net value [2] - The Huaxia SSE STAR 200 ETF has a current scale of 476 million yuan and has achieved a year-to-date return of 14.98%, ranking 260 out of 5,525 in its category [2] - The fund manager of the Huaxia SSE STAR 200 ETF is Hualong, who has been in the position for 3 years and 148 days, with the best fund return during this period being 139.26% [3]

Core Viewpoint - The stock of Hotgen Biotech has shown a mixed performance in recent trading, with a year-to-date increase of 18.12% but a slight decline over the past five days, indicating potential volatility in investor sentiment [1]. Financial Performance - For the period from January to September 2025, Hotgen Biotech reported a revenue of 310 million yuan, representing a year-on-year decrease of 19.80% [2]. - The company experienced a net loss attributable to shareholders of 109 million yuan, which is a significant decline of 168.12% compared to the previous year [2]. Shareholder and Market Activity - As of September 30, 2025, the number of shareholders increased by 12.90% to 7,833, while the average number of circulating shares per person decreased by 11.43% to 11,835 shares [2]. - The stock price reached 191.36 yuan per share with a market capitalization of 17.741 billion yuan, and the trading volume was 168 million yuan, indicating active market participation [1]. Dividends and Institutional Holdings - Since its A-share listing, Hotgen Biotech has distributed a total of 440 million yuan in dividends, with 17.344 million yuan paid out in the last three years [3]. - Among the top ten circulating shareholders, notable changes include a decrease in holdings by Huatai-PineBridge Innovation Medicine Mixed Fund and an increase by ICBC Frontier Medical Stock A [3].

证券日报网讯 1月12日，热景生物发布公告称，根据《上海证券交易所科创板股票做市交易业务实施细 则》相关规定，经广发证券股份有限公司备案申请，自2026年01月13日起，广发证券股份有限公司对科 创板股票热景生物（股票代码：688068）开展做市交易业务。 （文章来源：证券日报） ...

Core Viewpoint - The financing balance of the Sci-Tech Innovation Board decreased by 1.06 billion yuan, while the margin trading balance increased by 18.93 million yuan, indicating a mixed sentiment among investors [1]. Financing Balance Summary - As of January 9, the total margin trading balance on the Sci-Tech Innovation Board was 282.61 billion yuan, a decrease of 1.05 billion yuan from the previous trading day [1]. - The highest financing balance was held by Cambrian, with a balance of 15.35 billion yuan, followed by SMIC and Haiguang Information with balances of 13.03 billion yuan and 7.30 billion yuan, respectively [1]. - A total of 267 stocks saw an increase in financing balance, while 327 stocks experienced a decrease [1]. - Notable increases in financing balance were observed in Hotgen Biotech (56.65%), Yuyuan Pharmaceutical (54.61%), and Chipone Technology (39.46%) [1]. Margin Trading Balance Summary - Cambrian also had the highest margin trading balance at 41 million yuan, followed by Haiguang Information and SMIC with balances of 36 million yuan and 32 million yuan, respectively [2]. - A total of 264 stocks saw an increase in margin trading balance, while 148 stocks experienced a decrease [2]. - Significant increases in margin trading balance were noted for Huitong Co. (3360.47%), Yaxin Security (1268.15%), and Jinchengzi (805.25%) [2].

Core Viewpoint - The medical sector is experiencing significant activity, particularly driven by advancements in brain-computer interface (BCI) technology, which is attracting investor interest and leading to substantial market movements in related stocks and ETFs [3][10][11]. Market Performance - On January 6, 2026, the largest medical ETF (512170) saw a recovery, closing up 1.12% with a total trading volume of 1.017 billion yuan, marking two consecutive days of trading over 1 billion yuan [1][8]. - The ETF's index, which includes 12 related concept stocks, has a combined weight exceeding 36%, indicating strong sector representation [11][13]. Stock Highlights - Brain-computer interface stocks, such as Sanbo Brain Science and Meihua Medical, reached their daily limit up, while stocks like Yingke Medical and Hejing Biological experienced declines [1][8]. - The BCI sector is expected to see increased valuations for related listed companies, potentially boosting market financing and capital development [3][10]. Technological Advancements - A recent breakthrough in BCI technology was reported by Fudan University Huashan Hospital, which successfully completed the first clinical trial of a fully implanted, wireless, and functional BCI product [3][10]. - The BCI technology is positioned as a key area of investment, with potential applications in disease treatment and long-term enhancements for humans, opening up a market space worth trillions [10][11]. Investment Insights - According to CITIC Construction Investment, the current valuation of the medical index is 34.28 times, which is below the 70% threshold of the past decade, suggesting a favorable investment opportunity [4][11]. - The medical ETF (512170) is recognized as an efficient tool for accessing core medical assets, with a total size exceeding 26.4 billion yuan, making it the largest medical ETF in the market [6][13].

Core Viewpoint - Beijing Hotgen Biotech Co., Ltd. has established a successful model of "Beijing R&D, Hebei Production" to leverage regional advantages and enhance its production capacity in the field of in vitro diagnostics [1][2][3]. Group 1: Company Overview - Hotgen Biotech was founded in June 2005 and is headquartered in Daxing District, Beijing [1]. - The company focuses on innovative biotechnology solutions, including early disease screening, diagnosis, and treatment [1]. Group 2: Strategic Development - The company recognized the collaborative potential of Beijing, Tianjin, and Hebei around 2014-2015 and began exploring suitable locations for large-scale production [2]. - In 2016, Hotgen decided to establish a production base in Langfang, Hebei, to utilize the advantages of regional integration [2]. - The company has built a cross-regional collaboration system with R&D in Beijing and production in Hebei, enhancing efficiency in research and manufacturing [2][3]. Group 3: Financial and Operational Highlights - Hotgen's project for an annual production capacity of 12 million in vitro diagnostic reagents and 850 supporting instruments was funded with approximately RMB 287.82 million [2][3]. - Upon full production, the project is expected to generate annual revenue of approximately RMB 214.40 million and a net profit of about RMB 44.97 million, with an investment recovery period of 8.05 years [3]. - By 2024, the company anticipates achieving approximately RMB 511 million in revenue, primarily from in vitro diagnostic product sales [3]. Group 4: Product Development and Innovation - In December 2025, Hotgen received three medical device registration certificates, marking significant advancements in women's health, nutritional monitoring, and anemia management [4]. - The company is implementing a dual-driven strategy of "diagnostics + innovative drugs," focusing on antibody and nucleic acid drugs through partnerships with innovative pharmaceutical companies [5][6]. - Hotgen has established the "X-Gen AI New Drug Discovery and Design Research Center" to enhance drug development through advanced AI technologies [7].

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：688068 证券简称：热景生物 公告编号：2026-001 北京热景生物技术股份有限公司 二、回购股份的进展情况 根据《上市公司股份回购规则》《上海证券交易所上市公司自律监管指引第7号一一回购股份》等相关 规定，公司在实施回购期间，应当在每个月的前3个交易日内公告截至上月末的回购进展情况。现将公 司回购股份的进展情况公告如下：截至2025年12月31日，公司通过股份回购专用证券账户，以集中竞价 交易方式累计回购股份904,054股，占公司总股本92,707,940股的比例为0.98%，回购成交的最高价为 176.79元/股，最低价为145.59元/股，支付的资金总额为人民币149,955,134.73元（不含印花税、交易佣 金等交易费用）。 本次回购股份进展符合法律法规的规定及公司回购股份方案。 三、其他事项 公司将严格按照《上市公司股份回购规则》《上海证券交易所上市公司自律监管指引第7号一一回购股 份》等相关规定，在回购期限内根据市场情况择机做出回购决策并予以实施，同时根据回购股份事项进 展情况及时履行信息披露义务，敬请广大投资者注意投资风险。 ...